UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.161

Sortiert nach

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

Antimicrobial Agents and Chemotherapy, 1997-03, Vol.41 (3), p.654-660

1997

Link zum Volltext

Verfügbarkeit prüfen

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients

Journal of Virology, 2001-08, Vol.75 (16), p.7462-7469

2001

Link zum Volltext

Verfügbarkeit prüfen

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Antimicrobial Agents and Chemotherapy, 1998-12, Vol.42 (12), p.3218-3224

1998

Link zum Volltext

Verfügbarkeit prüfen

ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease and has High Oral Bioavailability in Humans

Proceedings of the National Academy of Sciences - PNAS, 1995-03, Vol.92 (7), p.2484-2488

1995

Link zum Volltext

Verfügbarkeit prüfen

An Enhanced Model of Middle Cerebral Artery Occlusion in Nonhuman Primates Using an Endovascular Trapping Technique

American journal of neuroradiology : AJNR, 2015-12, Vol.36 (12), p.2354-2359

2015

Link zum Volltext

Verfügbarkeit prüfen

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

AIDS (London), 1999-02, Vol.13 (2), p.213-224

1999

Link zum Volltext

Verfügbarkeit prüfen

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

AIDS (London), 1998-03, Vol.12 (5), p.F9-F14

1998

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

Journal of medicinal chemistry, 1998-02, Vol.41 (4), p.602-617

1998

Link zum Volltext

Verfügbarkeit prüfen

Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles

Journal of Virology, 1993-07, Vol.67 (7), p.4050-4055

1993

Link zum Volltext

Verfügbarkeit prüfen

Incidence of Resistance in a Double-Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine

The Journal of infectious diseases, 2004-01, Vol.189 (1), p.51-60

2004

Link zum Volltext

Verfügbarkeit prüfen

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

Journal of Virology, 1994-03, Vol.68 (3), p.2016-2020

1994

Link zum Volltext

Verfügbarkeit prüfen

NMR-Based Discovery of Lead Inhibitors That Block DNA Binding of the Human Papillomavirus E2 Protein

Journal of medicinal chemistry, 1997-09, Vol.40 (20), p.3144-3150

1997

Link zum Volltext

Verfügbarkeit prüfen

Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans

Drug metabolism and disposition, 1997-04, Vol.25 (4), p.489

1997

Link zum Volltext

Verfügbarkeit prüfen

Relationship between Adherence and the Development of Resistance in Antiretroviral-Naive, HIV-1—Infected Patients Receiving Lopinavir/Ritonavir or Nelfinavir

The Journal of infectious diseases, 2005-06, Vol.191 (12), p.2046-2052

2005

Link zum Volltext

Verfügbarkeit prüfen

Recent developments in HIV protease inhibitor therapy

Antiviral Research, 1998-07, Vol.39 (1), p.1-23

1998

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

Antimicrobial Agents and Chemotherapy, 2003-01, Vol.47 (1), p.350-359

2003

Link zum Volltext

Verfügbarkeit prüfen

Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol

Journal of medicinal chemistry, 1993-02, Vol.36 (3), p.320-330

1993

Link zum Volltext

Verfügbarkeit prüfen

Selection of Multiple Human Immunodeficiency Virus Type 1 Variants that Encode Viral Proteases with Decreased Sensitivity to an Inhibitor of the Viral Protease

Proceedings of the National Academy of Sciences - PNAS, 1994-06, Vol.91 (12), p.5597-5601

1994

Link zum Volltext

Verfügbarkeit prüfen

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

Nature medicine, 1996-07, Vol.2 (7), p.760-766

1996

Link zum Volltext

Verfügbarkeit prüfen

In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification

Drug metabolism and disposition, 1999-01, Vol.27 (1), p.86

1999

Link zum Volltext

Verfügbarkeit prüfen

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease

Antimicrobial Agents and Chemotherapy, 1991-11, Vol.35 (11), p.2209-2214

1991

Link zum Volltext

Verfügbarkeit prüfen

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor

Journal of Virology, 1995-02, Vol.69 (2), p.701-706

1995

Link zum Volltext

Verfügbarkeit prüfen

Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency Virus

Virology (New York, N.Y.), 1998-10, Vol.250 (2), p.255-262

1998

Link zum Volltext

Verfügbarkeit prüfen

Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia

Antimicrobial Agents and Chemotherapy, 2002-12, Vol.46 (12), p.3907-3916

2002

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor

Journal of Virology, 1998-09, Vol.72 (9), p.7532-7541

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.161

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(769)
Mit Volltextzugriff
(891)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease and has High Oral Bioavailability in Humans

An Enhanced Model of Middle Cerebral Artery Occlusion in Nonhuman Primates Using an Endovascular Trapping Technique

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles

Incidence of Resistance in a Double-Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

NMR-Based Discovery of Lead Inhibitors That Block DNA Binding of the Human Papillomavirus E2 Protein

Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans

Relationship between Adherence and the Development of Resistance in Antiretroviral-Naive, HIV-1—Infected Patients Receiving Lopinavir/Ritonavir or Nelfinavir

Recent developments in HIV protease inhibitor therapy

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol

Selection of Multiple Human Immunodeficiency Virus Type 1 Variants that Encode Viral Proteases with Decreased Sensitivity to an Inhibitor of the Viral Protease

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor

Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency Virus

Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia

In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor

Suchergebnisse filtern